Glucose- and interleukin-1β-induced β-cell apoptosis requires Ca2+ influx and extracellular signal-regulated kinase (ERK) 1/2 activation and is prevented by a sulfonylurea receptor 1/inwardly rectifying K+ channel 6.2 (SUR/Kir6.2) selective potassium channel opener in human islet

Diabetes

Volumn 53, Issue 7, 2004, Pages 1706-1713

  Maedler, Kathrin ^a   Størling, Joachim ^b   Sturis, Jeppe ^c   Zuellig, Richard A ^a   Spinas, Giatgen A ^a   Arkhammar, Per O G ^c   Mandrup Poulsen, Thomas ^b,d   Donath, Marc Y ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b STENO DIABETES CENTER   (Denmark)

^c Karolinska Institute ^*

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; DIAZOXIDE; GLUCOSE; INTERLEUKIN 1BETA; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NIMODIPINE; NN 414; POTASSIUM CHANNEL STIMULATING AGENT; SULFONYLUREA RECEPTOR; SULFONYLUREA RECEPTOR 1; TOLBUTAMIDE; UNCLASSIFIED DRUG; ABC TRANSPORTER; CALCIUM; DRUG RECEPTOR; FUSED HETEROCYCLIC RINGS; INTERLEUKIN 1; INWARDLY RECTIFYING POTASSIUM CHANNEL; MITOGEN ACTIVATED PROTEIN KINASE; POTASSIUM CHANNEL; SULFOXIDE;

ANTIBODY SPECIFICITY; APOPTOSIS; ARTICLE; CALCIUM TRANSPORT; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFECT; DRUG SELECTIVITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; MACROPHAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PANCREAS SECRETION; PRIORITY JOURNAL; WESTERN BLOTTING; AGED; CELL CULTURE; DRUG POTENTIATION; METABOLISM; MIDDLE AGED; PANCREAS ISLET; PHYSIOLOGY;

AGED; APOPTOSIS; ATP-BINDING CASSETTE TRANSPORTERS; BICYCLO COMPOUNDS, HETEROCYCLIC; CALCIUM; CALCIUM CHANNELS, L-TYPE; CELLS, CULTURED; CYCLIC S-OXIDES; DIAZOXIDE; DRUG SYNERGISM; ENZYME ACTIVATION; GLUCOSE; HUMANS; INTERLEUKIN-1; ISLETS OF LANGERHANS; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASES; POTASSIUM CHANNELS; POTASSIUM CHANNELS, INWARDLY RECTIFYING; RECEPTORS, DRUG; TOLBUTAMIDE;

EID: 3042825017     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.53.7.1706     Document Type: Article

References (60)

1. Bonner-Weir S: Islet growth and development in the adult. J Mol Endocrinol 24:297-302, 2000
2. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC: β-Cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 52:102-110, 2003
3. Cerasi E: Insulin deficiency and insulin resistance in the pathogenesis of NIDDM: is a divorce possible? Diabetologia 38:992-997, 1995
4. Gerich JE: Insulin resistance is not necessarily an essential component of type 2 diabetes. J Clin Endocrinol Metab 85:2113-2115, 2000
5. Kahn SE: The importance of the beta-cell in the pathogenesis of type 2 diabetes mellitus. Am J Med 108 (Suppl. 6a):2S-8S, 2000
6. Kahn SE: The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 46:3-19, 2003
7. Kloppel G, Lohr M, Habich K, Oberholzer M, Heitz PU: Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited. Surv Synth Pathol Res 4:110-125, 1985
8. Maclean N, Ogilvie RF: Quantitative estimation of the pancreatic islet tissue in diabetic subjects. Diabetes 4:367-376, 1955
9. Sakuraba H, Mizukami H, Yagihashi N, Wada R, Hanyu C, Yagihashi S: Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese type II diabetic patients. Diabetologia 45:85-96, 2002
10. Taylor SI, Accili D, Imai Y: Insulin resistance or insulin deficiency: which is the primary cause of NIDDM? Diabetes 43:735-740, 1994
11. Yoon KH, Ko SH, Cho JH, Lee JM, Ahn YB, Song KH, Yoo SJ, Kang MI, Cha BY, Lee KW, Son HY, Kang SK, Kim HS, Lee IK, Bonner-Weir S: Selective beta-cell loss and alpha-cell expansion in patients with type 2 diabetes mellitus in Korea. J Clin Endocrinol Metab 88:2300-2308, 2003
12. Henquin JC: Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes 49:1751-1760, 2000
13. Iwakura T, Fujimoto S, Kagimoto S, Inada A, Kubota A, Someya Y, Ihara Y, Yamada Y, Seino Y: Sustained enhancement of Ca(2+) influx by glibenclamide induces apoptosis in RINm5F cells. Biochem Biophys Res Commun 271:422-428, 2000
14. Efanova IB, Zaitsev SV, Zhivotovsky B, Kohler M, Efendic S, Orrenius S, Berggren PO: Glucose and tolbutamide induce apoptosis in pancreatic beta-cells: a process dependent on intracellular Ca2+ concentration. J Biol Chem 273:33501-33507, 1998
15. Maedler K, Carr RD, Bucher P, Berney T, Spinas GA, Donath MY: Differential effects of repaglinide, nateglinide and glibenclamide on apoptosis in human beta cells in vitro (Abstract). Diabetologia 46 (Suppl. 2):537, 2003
16. Greenwood RH, Mahler RF, Hales CN: Improvement in insulin secretion in diabetes after diazoxide. Lancet 1:444-447, 1976
17. Bjork E, Berne C, Kampe O, Wibell L, Oskarsson P, Karlsson FA: Diazoxide treatment at onset preserves residual insulin secretion in adults with autoimmune diabetes. Diabetes 45:1427-1430, 1996
18. Guldstrand M, Grill V, Bjorklund A, Lins PE, Adamson U: Improved beta cell function after short-term treatment with diazoxide in obese subjects with type 2 diabetes. Diabetes Metab 28:448-456, 2002
19. Carr RD, Brand CL, Bodvarsdottir TB, Hansen JB, Sturis J: NN414, a SUR1/Kir6.2-selective potassium channel opener, reduces blood glucose and improves glucose tolerance in the VDF Zucker rat. Diabetes 52:2513-2518, 2003
20. ATP channel opener. Diabetes 53:1089-1095, 2004
21. Ritzel RA, Hansen JB, Veldhuis JD, Butler PC: Induction of beta-cell rest by a Kir6.2/SUR1-selective K(ATP)-channel opener preserves beta-cell insulin stores and insulin secretion in human islets cultured at high (11 mM) glucose. J Clin Endocrinol Metab 89:795-805, 2004
22. Weir GC, Clore ET, Zmachinski CJ, Bonner-Weir S: Islet secretion in a new experimental model for non-insulin-dependent diabetes. Diabetes 30:590-595, 1981
23. Bonner-Weir S, Trent DF, Weir GC: Partial pancreatectomy in the rat and subsequent defect in glucose-induced insulin release. J Clin Invest 71: 1544-1553, 1983
24. Leahy JL, Cooper HE, Deal DA, Weir GC: Chronic hyperglycemia is associated with impaired glucose influence on insulin secretion: a study in normal rats using chronic in vivo glucose infusions. J Clin Invest 77:908-915, 1986
25. Unger RH, Grundy S: Hyperglycaemia as an inducer as well as a consequence of impaired islet cell function and insulin resistance: implications for the management of diabetes. Diabetologia 28:119-121, 1985
26. Eizirik DL, Korbutt GS, Hellerstrom C: Prolonged exposure of human pancreatic islets to high glucose concentrations in vitro impairs the beta-cell function. J Clin Invest 90:1263-1268, 1992
27. Kaiser N, Corcos AP, Sarel I, Cerasi E: Monolayer culture of adult rat pancreatic islets on extracellular matrix: modulation of B-cell function by chronic exposure to high glucose. Endocrinology 129:2067-2076, 1991
28. Marshak S, Leibowitz G, Bertuzzi F, Socci C, Kaiser N, Gross DJ, Cerasi E, Melloul D: Impaired β-cell functions induced by chronic exposure of cultured human pancreatic islets to high glucose. Diabetes 48:1230-1236, 1999
29. Robertson RP: Type II diabetes, glucose "non-sense," and islet desensitization. Diabetes 38:1501-1505, 1989
30. Rossetti L, Giaccari A, DeFronzo RA: Glucose toxicity. Diabetes Care 13:610-630, 1990
31. Ling Z, Kiekens R, Mahler T, Schuit FC, Pipeleers-Marichal M, Sener A, Kloppel G, Malaisse WJ, Pipeleers DG: Effects of chronically elevated glucose levels on the functional properties of rat pancreatic β-cells. Diabetes 45:1774-1782, 1996
32. Donath MY, Gross DJ, Cerasi E, Kaiser N: Hyperglycemia-induced β-cell apoptosis in pancreatic islets of Psammomys obesus during development of diabetes. Diabetes 48:738-744, 1999
33. Federici M, Hribal M, Perego L, Ranalli M, Caradonna Z, Perego C, Usellini L, Nano R, Bonini P, Bertuzzi F, Marlier LN, Davalli AM, Carandente O, Pontiroli AE, Melino G, Marchetti P, Lauro R, Sesti G, Folli F: High glucose causes apoptosis in cultured human pancreatic islets of Langerhans: a potential role for regulation of specific Bcl family genes toward an apoptotic cell death program. Diabetes 50:1290-1301, 2001
34. Maedler K, Spinas GA, Lehmann R, Sergeev P, Weber M, Fontana A, Kaiser N, Donath MY: Glucose induces β-cell apoptosis via upregulation of the Fas-receptor in human islets. Diabetes 50:1683-1690, 2001
35. Grill V, Bjorklund A: Overstimulation and β-cell function. Diabetes 50 (Suppl. 1):S122-S124, 2001
36. Sako Y, Grill VE: Coupling of β-cell desensitization by hyperglycemia to excessive stimulation and circulating insulin in glucose-infused rats. Diabetes 39:1580-1583, 1990
37. Mandrup-Poulsen T: The role of interleukin-1 in the pathogenesis of IDDM. Diabetologia 39:1005-1029, 1996
38. Maedler K, Sergeev P, Ris F, Oberholzer J, Joller-Jemelka HI, Spinas GA, Kaiser N, Halban PA, Donath MY: Glucose-induced beta-cell production of interleukin-1β contributes to glucotoxicity in human pancreatic islets. J Clin Invest 110:851-860, 2002
39. Larsen CM, Wadt KA, Juhl LF, Andersen HU, Karlsen AE, Su MS, Seedorf K, Shapiro L, Dinarello CA, Mandrup-Poulsen T: Interleukin-1beta-induced rat pancreatic islet nitric oxide synthesis requires both the p38 and extracellular signal-regulated kinase 1/2 mitogen-activated protein kinases. J Biol Chem 273:15294-15300, 1998
40. Pavlovic D, Andersen NA, Mandrup-Poulsen T, Eizirik DL: Activation of extracellular signal-regulated kinase (ERK)1/2 contributes to cytokine-induced apoptosis in purified rat pancreatic beta-cells. Eur Cytokine Netw 11:267-274, 2000
41. Ammendrup A, Maillard A, Nielsen K, Aabenhus AN, Serup P, Dragsbaek MO, Mandrup-Poulsen T, Bonny C: The c-Jun amino-terminal kinase pathway is preferentially activated by interleukin-1 and controls apoptosis in differentiating pancreatic β-cells. Diabetes 49:1468-1476, 2000
42. Dickson LM, Lingohr MK, McCuaig J, Hugl SR, Snow L, Kahn BB, Myers MG Jr, Rhodes CJ: Differential activation of protein kinase B and p70(S6)K by glucose and insulin-like growth factor 1 in pancreatic beta-cells (INS-1). J Biol Chem 276:21110-21120, 2001
43. Frodin M, Sekine N, Roche E, Filloux C, Prentki M, Wollheim CB, Van Obberghen E: Glucose, other secretagogues, and nerve growth factor stimulate mitogen-activated protein kinase in the insulin-secreting beta-cell line, INS-1. J Biol Chem 270:7882-7889, 1995
44. Hugl SR, White MF, Rhodes CJ: Insulin-like growth factor I (IGF-I)-stimulated pancreatic beta cell growth is glucose-dependent: synergistic activation of insulin receptor substrate-mediated signal transduction pathways by glucose and IGF-I in INS-1 cells. J Biol Chem 273:17771-17779, 1998
45. Khoo S, Cobb MH: Activation of mitogen-activating protein kinase by glucose is not required for insulin secretion. Proc Natl Acad Sci U S A 94:5599-5604, 1997
46. Lingohr MK, Dickson LM, McCuaig JF, Hugl SR, Twardzik DR, Rhodes CJ: Activation of IRS-2-mediated signal transduction by IGF-1, but not TGF-α or EGF, augments pancreatic β-cell proliferation. Diabetes 51:966-976, 2002
47. Briaud I, Lingohr MK, Dickson LM, Wrede CE, Rhodes CJ: Differential activation mechanisms of Erk-1/2 and p70(S6K) by glucose in pancreatic β-cells. Diabetes 52:974-983, 2003
48. Maggi LB Jr, Moran JM, Buller RM, Corbett JA: ERK activation is required for double-stranded RNA- and virus-induced interleukin-1 expression by macrophages. J Biol Chem 278:16683-16689, 2003
49. Linetsky E, Bottino R, Lehmann R, Alejandro R, Inverardi L, Ricordi C: Improved human islet isolation using a new enzyme blend, liberase. Diabetes 46:1120-1123, 1997
50. Oberholzer J, Triponez F, Mage R, Andereggen E, Buhler L, Cretin N, Fournier B, Goumaz C, Lou J, Philippe J, Morel P: Human islet transplantation: lessons from 13 autologous and 13 allogeneic transplantations. Transplantation 69:1115-1123, 2000
51. Ricordi C, Lacy PE, Finke EH, Olack BJ, Scharp DW: Automated method for isolation of human pancreatic islets. Diabetes 37:413-420, 1988
52. Gavrieli Y, Sherman Y, Ben-Sasson SA: Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119:493-501, 1992
53. Maedler K, Fontana A, Ris F, Sergeev P, Toso C, Oberholzer J, Lehmann R, Bachmann F, Tasinato A, Spinas GA, Halban PA, Donath MY: FLIP switches Fas-mediated glucose signaling in human pancreatic beta cells from apoptosis to cell replication. Proc Natl Acad Sci U S A 99:8236-8241, 2002
54. Lazar DF, Wiese RJ, Brady MJ, Mastick CC, Waters SB, Yamauchi K, Pessin JE, Cuatrecasas P, Saltiel AR: Mitogen-activated protein kinase kinase inhibition does not block the stimulation of glucose utilization by insulin. J Biol Chem 270:20801-20807, 1995
55. Kendall DM, Sutherland DE, Najarian JS, Goetz FC, Robertson RP: Effects of hemipancreatectomy on insulin secretion and glucose tolerance in healthy humans. N Engl J Med 322:898-903, 1990
56. Kjems LL, Kirby BM, Welsh EM, Veldhuis JD, Straume M, McIntyre SS, Yang D, Lefebvre P, Butler PC: Decrease in β-cell mass leads to impaired pulsatile insulin secretion, reduced postprandial hepatic insulin clearance, and relative hyperglucagonemia in the minipig. Diabetes 50:2001-2012, 2001
57. Weir GC, Leahy JL, Bonner-Weir S: Experimental reduction of B-cell mass: implications for the pathogenesis of diabetes. Diabetes Metab Rev 2:125-161, 1986
58. Chen MC, Proost P, Gysemans C, Mathieu C, Eizirik DL: Monocyte chemoattractant protein-1 is expressed in pancreatic islets from prediabetic NOD mice and in interleukin-1 beta-exposed human and rat islet cells. Diabetologia 44:325-332, 2001
59. Eizirik DL, Darville MI: β-Cell apoptosis and defense mechanisms: lessons from type 1 diabetes. Diabetes 50 (Suppl. 1):S64-S69, 2001
60. Dabrowski M, Larsen T, Ashcroft FM, Bondo HJ, Wahl P: Potent and selective activation of the pancreatic beta-cell type K(ATP) channel by two novel diazoxide analogues. Diabetologia 46:1375-1382, 2003